Program Schedule

594
Malaria - Prospects for Elimination

Session: Symposium: Updates on Major ID: TB, Malaria, and Typhoid
Friday, October 10, 2014: 9:30 AM
Room: The Pennsylvania Convention Center: 120-ABC
Philip Rosenthal, MD, University of California, San Francisco, CA

Philip J. Rosenthal
Dr. Rosenthal received his BS in Biochemistry from SUNY at Stony Brook and his medical degree from New York University. He completed his medical residency at the University of Michigan, followed by an Infectious Diseases Fellowship at UCSF. He joined the faculty at UCSF in the Department of Medicine, Division of Infectious Diseases in 1988, and he is now a Professor in the Department. Dr. Rosenthal was a consultant for the World Health Organization early in his career, working with the Program on AIDS in Malawi. Recently, he was the Director of the Innovative Translational Collaboration program of the UCSF Clinical and Translational Science Institute (CTSI). He is a member of the Biomedical Sciences Graduate program and the Global Health Sciences Program, and co-directs a GHS course on Communicable Diseases of Global Health Importance. Dr. Rosenthal serves on numerous university committees, has participated on many study sections of the NIH and other research funders, and is currently a member of the World Health Organization Tropical Disease Research Expert Drug Discovery Advisory Committee and the Multilateral Initiative on Malaria/ Tropical Disease Research Task Force on Research Capability Strengthening in Africa. Dr. Rosenthalís research interests are focused on multiple aspects of malaria, including the biochemistry of malaria parasites, antimalarial drug discovery, and clinical and translational studies of antimalarial drug efficacy and resistance in Africa. Basic science studies center on the characterization of a family of proteases that play a key role in the parasite life cycle. Drug discovery work includes collaborations with a number of chemistry groups to develop new antimalarial drugs, in particular inhibitors of proteases. Translational work in Uganda and Burkina Faso includes randomized trials of new antimalarial therapies, evaluations of malaria in cohorts of children, evaluations of HIV-malaria co-infection, studies of new malaria diagnostic strategies, evaluations of drug pharmacokinetics, and the longitudinal assessment of the impacts of host genetics, parasite genetics, antimalarial immunity, and epidemiological factors on the incidence of malaria. Dr. Rosenthal is the recipient of a Doris Duke Charitable Foundation Distinguished Clinical Scientist Award. His work has also been funded by the National Institutes of Health, Centers for Disease Control, and Medicines for Malaria Venture. He has published over 200 scientific articles and book chapters on malaria and related topics.



<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek